The results revealed a significant positive correlation between CXCR6 expression and CD8A (Figure 5A), effector T cell signature (Figure 5B), and CD274 (PD-L1) (Figure 5C) in bladder cancer, suggesting that CXCR6 may hold potential as a predictive biomarker for immunotherapy response. This evidence concerns the gene CXCR6 and urinary bladder carcinoma.